10KSB

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                          ----------------------------

                                   FORM 10-KSB

(Mark One)

[X]  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the Fiscal Year Ended JUNE 30, 2001
                          -------------

                                       OR

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For transition period from ____ to ____


                        Commission File Number 001-10647
                                               ---------


                       PRECISION OPTICS CORPORATION, INC.
                 (Name of small business issuer in its charter)


          MASSACHUSETTS                                         04-279-5294
  (State or other jurisdiction                               (I.R.S. Employer
of incorporation or organization)                           Identification No.)


                                22 EAST BROADWAY
                          GARDNER, MASSACHUSETTS 01440
               (Address of principal executive offices) (Zip Code)


                                 (978) 630-1800
                (Issuer's telephone number, including area code)


              Securities registered under Section 12(b) of the Act:
                                      NONE


              Securities registered under Section 12(g) of the Act:
                          COMMON STOCK, $.01 PAR VALUE

         Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes X  No
                                                                      ---   ---

         Check if no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is contained in this form, and no disclosure will be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB.  X
                               ---

         The issuer's revenues for its most recent fiscal year were $4,247,828.

         The aggregate market value of the voting stock, consisting solely of
common stock, held by non-affiliates of the issuer computed by reference to the
closing price of such stock was $5,555,069 as of August 31, 2001.

         The number of shares of outstanding common stock of the issuer as of
August 31, 2001 was 10,503,908.

                       DOCUMENTS INCORPORATED BY REFERENCE

         The issuer's Proxy Statement for the 2001 Annual Meeting of
Shareholders to be held on November 13, 2001 is incorporated into Part III of
this Form 10-KSB.




                                     PART I

ITEM 1.  DESCRIPTION OF BUSINESS

         BUSINESS DEVELOPMENT

         Precision Optics Corporation, Inc. (the "Company") was incorporated in
Massachusetts in 1982 and has been publicly owned since November 1990.

         References to the Company contained herein include its two wholly owned
subsidiaries except where the context otherwise requires.

         BUSINESS OF ISSUER

         The Company designs, develops, manufactures and sells specialized
optical systems and components and optical thin film coatings. The Company
conducts business in one industry segment only. The Company's products and
services fall into the following areas: medical products for use by hospitals
and physicians, optical thin films used in telecommunications and other
applications, test instrumentation, and advanced optical system design and
development services.

PRINCIPAL PRODUCTS AND SERVICES AND METHODS OF DISTRIBUTION.

         OPTICAL THIN FILMS. Optical thin film filters are used as the key
components for devices which can separate laser communication signals into
constituent wavelengths (i.e., colors) of very narrow bandwidths. By separating
a communication signal into its constituent wavelengths, it is possible to
create additional communication channels and thereby increase the transmission
capacity of a fiber optic communication line. The technique of separating
communication signals into constituent wavelengths of very narrow bandwidths to
increase transmission capacity in fiber optic communication lines is called
Dense Wavelength Division Multiplexing (DWDM). The devices that perform this
separation technique, composed of one or more optical thin film filters and a
means of being attached to a fiber optic communication line, are called Dense
Wavelength Division Multiplexers.

         The Company's DWDM optical thin film filters are designed to withstand
changes in temperature and humidity, consistent with customers' environmental
requirements for passive components.

         In 1997, the Company announced efforts to develop prototype DWDM
optical filters based upon ion-assisted electron beam deposition technology
developed by the Company in the early 1990s. Ion-assisted electron beam
deposition is a process of depositing a large number of ultra-thin layers of
material on a glass substrate within a vacuum chamber. For filters with channel
separation as low as 100 GHz, this technology and its variations are presently
widely used. Channel separation refers to the difference in frequency between
channels. A lower frequency difference (e.g., 100GHz as compared with 200GHz)
allows a greater number of channels to be transmitted.

         First deliveries of 200 GHz DWDM filters were made in March 1999.
Prototypes of 100 GHz DWDM filters have been produced and distributed to key
customers and potential customers for testing and evaluation.

         DWDM FILTER TEST INSTRUMENTATION. In March 2001, the Company introduced
two major new products at the Optical Fiber Communication Conference (OFC) trade
show - the manual Gen IIITM DWDM Test Fixture for characterizing
telecommunications filters and a fully automated filter testing system. Both
products are based on patent-pending technology and allow greatly enhanced speed
and accuracy in the measurement of filters. Shipments of manual test fixtures
commenced during fiscal year 2001. Product development is continuing on the
automated filter testing system, with initial sales anticipated during fiscal
year 2002.


                                       2



         MEDICAL PRODUCTS. The Company's medical products include endoscopes, as
well as image couplers, beamsplitters and adapters, all of which are used as
accessories to endoscopes.

         Since January 1991, the Company has developed and sold endoscopes using
various optical technologies for use in a variety of minimally invasive surgical
and diagnostic procedures. The Company's current line of specialized endoscopes
include arthroscopes (which are used in joint surgery), laryngoscopes (which are
used in the diagnosis of diseases of the larynx), laparoscopes (which are used
in abdominal surgery) and stereo endoscopes and cameras (which are used in
cardiac surgery). In addition to its existing line of endoscopes, the Company is
continuing to develop different types of endoscopes that incorporate varying
types of construction and technology for use in various medical specialties.

         The Company developed and has manufactured and sold since 1985 a
proprietary product line of instrumentation to couple endoscopes to video
cameras. Included in this product line are imaging couplers, which physically
connect the endoscope to a video camera system and transmit the image viewed
through the scope to the video camera. Another product, the beamsplitter,
performs the same function while preserving for the viewer an eyeport for
direct, simultaneous viewing through the endoscope. The Company has sold these
devices primarily to endoscope and video camera manufacturers and suppliers for
resale under the Company's customers' names.

         The Company's image couplers and beamsplitters can withstand
surgery-approved sterilization. The Company also offers autoclavable image
couplers, which are able to withstand sterilization in superheated steam under
pressure. Autoclavability is a preferred method of sterilization because of its
relative speed, safety, and efficiency. The Company believes that it is the only
company in the world that produces autoclavable image couplers.

         Included in the Company's medical products sales are sales of image
couplers and beamsplitters for video-monitored examination of a variety of
industrial cavities and interiors. The Company has developed, and may develop in
the future, specialized borescopes for industrial applications.

         OPTICAL SYSTEM DESIGN AND DEVELOPMENT SERVICES. The Company provides on
a contract basis advanced lens design, imaging analysis, optical system design,
structural design and analysis, prototype production and evaluation, optics
testing, and optical system assembly. Some of the Company's development
contracts have led to optical system production business for the Company, and
the Company believes its prototype development service may lead to new product
production from time to time.

COMPETITION AND MARKETS.

         The areas in which the Company does business are highly competitive and
include both foreign and domestic competitors. Many of the Company's competitors
are larger and have substantially greater resources than the Company.
Furthermore, other domestic or foreign companies, some with greater experience
in the optics industry and greater financial resources than the Company, may
seek to produce products or services that compete with those of the Company. The
Company may establish or use production facilities overseas to produce key
components for the Company's business, such as lenses. The Company believes that
the cost savings from such production may be essential to the Company's ability
to compete on a price basis in the medical products area particularly and to the
Company's profitability generally.

         The Company believes that competition for sales of its medical products
and services, which have been principally sold to Original Equipment
Manufacturer (OEM) customers, is based on performance and other technical
features, as well as other factors, such as scheduling and reliability, in
addition to competitive price.


                                       3



         The Company currently sells its image couplers, beamsplitters, and
adapters to a market that consists of approximately 30 to 35 potential OEM
customers. These potential customers sell video cameras, endoscopes, or
video-endoscopy systems. The Company has made sales to approximately two thirds
of these customers. The Company estimates that it has approximately 20% to 30%
of the market share in these products. The Company's primary competition in this
area is the customers' own in-house capabilities to manufacture such products.
The Company believes that these customers typically purchase products from the
Company, despite their in-house capabilities, because they choose to devote
their own technical resources to their primary products, such as cameras or
endoscopes. The Company estimates that approximately 50% of the market demand
for image couplers, beamsplitters, and adapters is met by "captive" or in-house
capabilities.

         The Company has marketed and sold its endoscopes to OEM video camera
and video endoscopy suppliers for resale under the purchaser's name. A number of
domestic and foreign competitors also sell endoscopes to such OEM suppliers, and
the Company's share of the endoscope market is nominal. The Company believes
that, while its resources are substantially more limited than these competitors,
the Company can compete successfully in this market on the basis of price and
delivery.

         The market for DWDM products is a multi-tiered market consisting of (1)
services providers (end users) such as AT&T, Sprint, MCI, WorldCom, and others,
(2) systems integrators such as Lucent, Nortel, Ciena, Alcatel, and others; and
(3) device and subsystem manufacturers such as JDS Uniphase, Corning, DiCon
Fiberoptics and numerous smaller companies estimated to number in the range of
30 to 40 who use DWDM filters as integral components of their devices. The
Company's primary customers for DWDM filters are such device and subsystem
manufacturers.

         The Company's thin film coatings competitors are numerous and have deep
and broad capabilities. Some of the companies in categories (2) and (3) above
have in-house capability to manufacture DWDM filters. The Company believes that
the number of stand-alone companies who currently have the capability to
manufacture DWDM filters is less than ten.

         Business prospects for the Company's DWDM filters remain uncertain
largely because of lack of visibility concerning future spending levels for
telecommunications equipment. The Company believes that downward trends in the
selling prices of DWDM filters may continue because of existing inventory
surpluses, increasing competitive pressure, and softening demand experienced by
telecommunications equipment providers.

         The market for DWDM test instrumentation consists of companies who
manufacture DWDM filters, as well as device manufacturers who use DWDM filters
as integral components of their devices. The Company's competitors in this
market consist of several foreign and domestic companies, some of whom are
larger and have substantially greater resources than the Company. The Company
believes that, while its resources may be substantially more limited than these
competitors, it can compete successfully on the basis of price and ease of use
of its instruments.

         The Company offers advanced optical design and development services not
related to thin film coatings to a wide range of potential customers and has
numerous competitors. The ability to supply design and development services to
such customers is highly dependent upon a company's and its employees'
reputations and prior experience.

         The Company has had negligible direct export sales to date.


                                       4



RESEARCH AND DEVELOPMENT.

         The Company believes that its future success depends to a large degree
on its ability to continue to conceive and to develop new optical products and
services to enhance the performance characteristics and methods of manufacture
of existing products. Accordingly, it expects to continue to seek to obtain
product-related design and development contracts with customers and to invest
its own funds on its research and development.

         The Company spent approximately $3,215,000 and $1,694,000 of its own
funds during fiscal years 2001 and 2000, respectively, on the Company's own
research and development. The Company received approximately $6,000 and $10,000
for the fiscal years ended June 30, 2001 and 2000, respectively, from customers
for customer-sponsored design and development projects. Levels of customer
contract funded research and development can fluctuate greatly in any given
period depending upon the mix between design efforts and hardware development,
which is generally more expensive and time consuming than the design phases.

RAW MATERIALS AND PRINCIPAL SUPPLIERS.

         For all of the Company's products, except for thin film coatings, the
basic raw material is precision grade optical glass, which the Company obtains
from several major suppliers. Outside vendors grind and polish most of the
Company's lenses and prisms. For optical thin film coatings, the basic raw
materials are metals and dielectric compounds, which the Company obtains from a
variety of chemical suppliers. The Company believes that its demand for these
raw materials and services is small relative to the total supply and that
materials and services required for the production of its products are currently
available in sufficient production quantities and will be available for fiscal
year 2002. The Company believes, however, that there are relatively few
suppliers of the high quality lenses and prisms which its endoscopes may
require. The Company has therefore established an in-house optical shop for
producing ultra-high quality prisms, micro-optics and other specialized optics
for a variety of medical and industrial applications. Depending upon the market
acceptance of the Company's endoscopes, the Company may seek to assure itself of
a timely supply of lenses, prisms, or other key materials or components through
the acquisition of an outside supplier or expanded in-house manufacturing
facilities.

PATENTS AND TRADEMARKS.

         The Company relies, in part, upon patents, trade secrets, and
proprietary knowledge as well as personnel policies and employee confidentiality
agreements concerning inventions and other creative efforts to develop and to
maintain its competitive position. The Company does not believe that its
business is dependent upon any patent, patent pending, or license, although it
believes that trade secrets and confidential know-how may be important to the
Company's scientific and commercial success.

         The Company plans to file for patents, copyrights, and trademarks in
the United States and in appropriate countries to protect its intellectual
property rights to the extent practicable. The Company holds the rights to
several United States and foreign patents and has several patent applications
pending. The Company knows of no infringements of its patents. The Company plans
to protect its patents from infringement in each instance where it determines
that doing so would be economical in light of the expense involved and the level
and availability of the Company's financial resources. While the Company
believes that its pending applications relate to patentable devices or concepts,
there can be no assurance that patents will be issued or that any patents issued
can be successfully defended or will effectively limit the development of
competitive products and services.


                                       5



EMPLOYEES.

         As of June 30, 2001, the Company had seventy eight full-time employees
and 3 part-time employees. There were 53 employees in manufacturing, 16 in
engineering, 5 in sales and marketing, and 7 in finance and administration.

CUSTOMERS.

         Sales to the Company's two largest customers, in terms of total sales
during fiscal year 2000, were approximately 46% and 11%, respectively, and
during fiscal year 2001, were approximately 41% and 18%, respectively.

ENVIRONMENTAL PROTECTION AND THE EFFECT OF EXISTING OR PROBABLE GOVERNMENT
REGULATIONS ON THE BUSINESS.

         The Company's operations are subject to a variety of federal, state,
and local laws and regulations relating to the discharge of materials into the
environment or otherwise relative to the protection of the environment. From
time to time the Company uses a small amount of hazardous materials in its
operations. The Company believes that it complies with all applicable
environmental laws and regulations.

NEED FOR GOVERNMENT APPROVAL OF PRINCIPAL PRODUCTS OR SERVICES AND EFFECT OF
EXISTING OR PROBABLE GOVERNMENT REGULATIONS ON THE BUSINESS.

         The Company currently sells and markets several medical products, the
marketing of which may require the permission of the United States Food and Drug
Administration ("FDA"). Pursuant to the Company's notification to the FDA of its
intent to market its endoscopes, image couplers, beamsplitters, and adapters,
the FDA has determined that the Company may market such devices, subject to the
general controls provisions of the Food, Drug and Cosmetic Act. This FDA
permission was obtained without the need to undergo a lengthy and expensive
approval process, on account of the FDA's determination that such devices meet
the regulatory standard of being substantially equivalent to an existing
approved device. Furthermore, the Company plans to market additional endoscopes
and related medical products that may require the FDA's permission to market
such products. The Company may also develop additional products or seek to sell
some of its current or future medical products in a manner that requires the
Company to obtain the permission of the FDA to market such products, as well as
the regulatory approval or license of other federal, state, and local agencies
or similar agencies in other countries. The FDA has authority to conduct
detailed inspections of manufacturing plants in order to assure that "good
manufacturing practices" are being followed in the manufacture of medical
devices, to require periodic reporting of product defects to the FDA, and to
prohibit the sale of devices which do not comply with law.

ITEM 2.  DESCRIPTION OF PROPERTY

         The Company conducts its domestic operations at three facilities in
Gardner, Massachusetts. The main Gardner facility is leased from a corporation
owned by an officer-shareholder-director of the Company. The lease terminated in
December 1999 and the Company is currently a tenant at will. The other Gardner
facility is under a five-year lease which commenced on March 1, 1999. In August
2000 the Company entered into a five-year lease for approximately 37,400 square
feet of additional space to be used for its Optical Thin Film operations. The
lease contains a renewal option and an option on additional space. Operations in
the new facility commenced during the quarter ending December 31, 2000. The
Company rents office space in Hong Kong for sales, marketing and supplier
quality control and liaison activities of its Hong Kong subsidiary.

         The Company believes these facilities are adequate for its current
operations. Significant increases in production or the addition of significant
equipment additions or manufacturing capabilities in connection with the
production of the Company's line of endoscopes, optical thin films, and other
products may, however,


                                       6



require the acquisition or lease of additional facilities. The Company may
establish production facilities domestically or overseas to produce key
assemblies or components, such as lenses, for the Company's products. Overseas
facilities may subject the Company to the political and economic risks
associated with overseas operations. The loss of or inability to establish or
maintain such additional domestic or overseas facilities could materially
adversely affect the Company's competitive position and profitability.

ITEM 3.  LEGAL PROCEEDINGS

         None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         No matters were submitted to a vote of the Company's security holders
during the fourth quarter of fiscal year 2001.


                                       7



                 DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

         The Company's executive officers and directors are as follows:




                                                 POSITION WITH THE COMPANY
NAME                                             OR PRINCIPAL OCCUPATION
----                                             -------------------------
                                              
Richard E. Forkey                                Chairman of the Board, Chief Executive
                                                 Officer, President, Treasurer and
                                                 Director

Jack P. Dreimiller                               Senior Vice President,
                                                 Finance, Chief Financial
                                                 Officer and Clerk

James D. Rancourt                                Senior Vice President,
                                                 Optical Thin Film Technology

Edward A. Benjamin                               Director. Member of Audit Committee. Mr. Benjamin
                                                 is a retired partner in the law firm of Ropes &
                                                 Gray, Boston, Massachusetts.

H. Angus Macleod                                 Director. Dr. Macleod is President of the Thin
                                                 Film Center, Inc. of Tucson, Arizona, which
                                                 provides software consulting and courses for design
                                                 and analysis of thin film optical coatings and
                                                 filters.

Austin W. Marxe                                  Director. Mr. Marxe is Managing Director of
                                                 Special Situations Fund III, L.P., a registered
                                                 investment company based in New York City, and
                                                 several other affiliated investment funds.

Joel R. Pitlor                                   Director. Member of Audit Committee. Mr. Pitlor
                                                 is president of J.R. Pitlor, a management
                                                 consulting firm based in Cambridge, Massachusetts.

Robert R. Shannon                                Director. Member of Audit Committee. Mr. Shannon
                                                 is a professor at the Optical Sciences Center of
                                                 the University of Arizona in Tucson, Arizona.



                                       8



                                     PART II


ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

         The Company's common stock is listed on the National Association of
Securities Dealers Automated Quotation (NASDAQ) System under the symbol "POCI."
Since January 1992, the NASDAQ SmallCap Market has been the principal market in
which the Company's stock is publicly traded. The high and low sales prices for
the Company's stock for each full quarterly period within the two most recent
fiscal years were as follows:




                            2000                                     2001
                            ----                                     ----
Quarter           High                 Low                High                 Low
                  ------------------------------------------------------------------
                                                                   
First             $1.50                $.94               $20.25               $7.50

Second            $20.25               $.94               $8.56                $1.81

Third             $41.75               $11.25             $5.59                $1.63

Fourth            $19.19               $5.81              $2.55                $1.22



         As of August 31, 2001, there were approximately 90 holders of record of
the Company's common stock.

         The Company has not declared any dividends during the last two fiscal
years. At present, the Company intends to retain its earnings, if any, to
finance research and development and expansion of its business.


                                       9



ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS

IMPORTANT FACTORS REGARDING FORWARD-LOOKING STATEMENTS

         When used in this discussion, the words "believes", "anticipates",
"intends to", and similar expressions are intended to identify forward-looking
statements. Such statements are subject to certain risks and uncertainties which
could cause actual results to differ materially from those projected. These
risks and uncertainties, many of which are not within the Company's control,
include, but are not limited to, the uncertainty and timing of the successful
development of the Company's new products, particularly in the optical thin
films area, the risks associated with reliance on a few key customers; the
Company's ability to attract and retain personnel with the necessary scientific
and technical skills, the timing and completion of significant orders; the
timing and amount of the Company's research and development expenditures; the
timing and level of market acceptance of customers' products for which the
Company supplies components; performance of the company's vendors; the ability
of the Company to control costs associated with performance under fixed price
contracts; and the continued availability to the Company of essential supplies,
materials and services; which are described further in Exhibit 99 hereto.
Readers are cautioned not to place undue reliance on these forward looking
statements, which speak only as of the date hereof. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.

LIQUIDITY AND CAPITAL RESOURCES

         For the year ended June 30, 2001, the Company's cash and cash
equivalents decreased by approximately $4,598,000 to $10,530,000. The decrease
in cash and cash equivalents was due to cash used by operating activities of
approximately $3,448,000, capital expenditures of approximately $3,617,000,
repayment of capital lease obligation of approximately $96,000, expenses of
approximately $17,000 associated with a private placement of common stock in
fiscal year 2000, and an increase in other assets (primarily patents) of
approximately $28,000, partially offset by net proceeds received of
approximately $2,369,000 from settlement of litigation and proceeds received of
approximately $239,000 from exercise of stock options and warrants.

         In March 2000, the Company completed a private placement of 789,463
shares of common stock with gross proceeds of approximately $15,000,000. In
conjunction with this offering, the purchasers and placement agent were issued
warrants to acquire an aggregate of 465,798 shares of common stock at a weighted
average exercise price of $26.73 per share. The warrants are immediately
exercisable and expire on March 17, 2005.

         In August 2000, the Company entered into a five-year lease for
additional space for a new Optical Thin Films Technology Center to be devoted to
development and manufacturing of optical thin films for telecommunications and
other applications. Operations in the new facility commenced during the quarter
ended December 31, 2000.

         The Company intends to continue devoting resources to internally-funded
research and development spending on both new products and the improvement of
existing products. The Company also intends to devote resources to the marketing
and product support of its medical and optical thin films product lines. These
investments may temporarily result in negative cash flow, but the Company
anticipates that the results of these efforts will translate into increased
revenues and profits.

         The Company's cash and cash equivalents are considered sufficient to
support working capital and investment needs for at least the next twelve
months.


                                       10



RECENT ACCOUNTING PRONOUNCEMENTS

         In June 1999, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards ("SFAS") No. 137, ACCOUNTING FOR
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - DEFERRAL OF THE EFFECTIVE DATE
OF FASB STATEMENT NO. 133, which defers the effective date of SFAS No. 133 to
all fiscal quarters of all fiscal years beginning after June 15, 2000. SFAS No.
133, ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES, establishes
accounting and reporting standards for derivative instruments, including certain
derivative instruments embedded in other contracts, and for hedging activities.
It requires entities to recognize all derivatives as either assets or
liabilities in the statement of financial position and measure those instruments
at fair value. The adoption of this new accounting standard did not have a
material impact on the Company's financial statements.

         In July 2001, the Financial Accounting Standards Board (FASB) issued
SFAS No. 141, BUSINESS COMBINATIONS. SFAS No. 141 requires all business
combinations initiated after June 30, 2001 to be accounted for using the
purchase method. This statement is effective for all business combinations
initiated after June 30, 2001.

         In July 2001, the FASB issued SFAS No. 142, GOODWILL AND OTHER
INTANGIBLE ASSETS. This statement applies to goodwill and intangible assets
acquired after June 30, 2001, as well as goodwill and intangible assets
previously acquired. Under this statement goodwill as well as certain other
intangible assets, determined to have an infinite life, will no longer be
amortized; instead these assets will be reviewed for impairment on a periodic
basis. This statement is effective for the Company for the first quarter in the
fiscal year ended June 2002. The adoption of this new accounting standard is not
expected to have a material impact on the Company's financial statements.

FISCAL YEAR 2001 RESULTS OF OPERATIONS

         Total revenues for fiscal year 2001 increased by approximately
$1,238,000 or 41.1% from fiscal year 2000.

         The revenue increase from the prior year was due to higher sales of
medical products (up 11%), and higher sales of non-medical products (up 225%).
Medical sales were higher due primarily to higher sales of stereo endoscopes and
endoscopic cameras, and non-stereo endoscopes. Non-medical sales were higher due
primarily to higher sales of DWDM filters and initial sales of DWDM test
instrumentation.

             Revenues from the Company's two largest customers were
approximately 41% and 18%, respectively, of total revenues for fiscal year 2001.
Revenues from the Company's two largest customers were approximately 46% and
11%, respectively, of total revenues for fiscal year 2000. Revenues from the
Company's largest customer were approximately 37% of total revenues for fiscal
year 1999. No other customers accounted for more than 10% of the Company's
revenues during those periods.

             Gross profit decreased by approximately $235,000 in fiscal year
2001, and as a percentage of revenue decreased from 34.7% to 19.0%, compared to
the previous year. The decrease in the gross profit percentage was due primarily
to higher fixed manufacturing costs resulting from increased personnel,
significant capital expenditures and the commencement of operations in a new
optical thin film technology facility, and lower average selling prices for DWDM
filters.

              Research and development expenses increased by approximately
$1,521,000, or 89.8%, during fiscal year 2001 compared to the previous year.
During both years, research and development expenses consisted primarily of
development efforts related to DWDM filters used in telecommunications systems.
The increase was due to more resources being devoted to the DWDM filter project
in the current year, and to the commencement of product development efforts on a
new product line - filter test equipment.

              Selling, general and administrative expenses increased by
approximately $344,000, or 19.5%, during fiscal year 2001 compared to the
previous year. The increase was due primarily to higher sales and marketing


                                       11



headcount, employee recruiting, insurance, advertising and trade show expenses,
and higher provisions for estimated uncollectable customer accounts. Also
contributing to the increase was recognition of approximately $32,000 of
non-cash compensation expense for non-employee stock options in accordance with
Emerging Issues Task Force 00-19, ACCOUNTING FOR DERIVATIVE FINANCIAL
INSTRUMENTS INDEXED TO AND POTENTIALLY SETTLED IN, A COMPANY'S OWN STOCK.

              Interest expense relates primarily to capital lease obligations
and decreased by approximately $12,000 or 51.2% during fiscal year 2001 due to
the lower average debt balance.

              Interest income increased by approximately $500,000 or 178.7%
during fiscal year 2001 compared to the previous year. The increase was due to
the higher base of cash and cash equivalents related primarily to net proceeds
received from a private placement of common stock in March 2000, from exercise
of stock options and warrants, and from net proceeds received from settlement of
litigation.

         The income tax provision in fiscal year 2001 represents the minimum
statutory state income tax liability.

FISCAL YEAR 2000 RESULTS OF OPERATIONS

         Total revenues for fiscal year 2000 were approximately $3,010,000, a
decrease of approximately $19,000, or 0.6% from fiscal year 1999.

         The revenues decrease from the prior year was due to lower sales of
non-medical products (down 25%) partially offset by higher sales of medical
products (up 5%). Non-medical sales were lower due to the phasing out of night
vision products, partially offset by slightly higher sales of Dense Wavelength
Division Multiplexer (DWDM) filters used in telecommunications systems (up
3.4%). DWDM filter sales represented approximately 10% of total revenues for
fiscal year 2000. Sales of medical products were higher due primarily to higher
shipments of stereo endoscopes and cameras.

         Gross profit increased by approximately $170,000 in fiscal year 2000,
and as a percentage of revenue increased from 28.8% to 34.7% compared to the
previous year. The increase in gross profit and the gross profit percentage was
due primarily to higher sales of medical products with a more favorable product
mix in the current year, partially offset by higher fixed manufacturing costs
such as depreciation, employee recruiting, equipment rental and indirect labor.

         Research and development expenses increased by approximately $753,000
or 80% during fiscal year 2000 compared to the previous year. Approximately 85%
of the research and development expenses in fiscal year 2000 related to DWDM
filters. Efforts were focused on improving manufacturing processes for 200 GHz
DWDM filters and development of 100 GHz DWDM filters. The increase was due to
significantly more resources being devoted to the DWDM filter project during
fiscal year 2000.

         Selling, general and administrative expenses increased by $151,000 or
9.4% during fiscal year 2000 compared to the previous year. The increase was due
primarily to higher professional services, insurance, and payroll related
expenses.

         Interest expense relates primarily to capital lease obligations and
decreased by approximately $3,000 or 10.4% during fiscal year 2000 due to the
lower average debt balance.

         Interest income increased by approximately $240,000 during fiscal year
2000 compared to the previous year. The increase was due to the higher base of
cash and cash equivalents related to net proceeds received from private
placements of common stock in August 1999 and March 2000 and from exercise of
stock options and warrants.


                                       12



         The income tax provision in fiscal year 2000 represents the minimum
statutory state income tax liability.

TRENDS AND UNCERTAINTIES THAT MAY AFFECT FUTURE RESULTS

PRODUCT AND INFRASTRUCTURE DEVELOPMENT

     The Company has continued to invest aggressively in research, development
and capital equipment to support increased participation in the long-term
opportunities the telecommunications industry offers. In particular, work has
accelerated on improved, higher-capacity manufacturing processes for 200 GHz
filter production, and development and commercialization of 100 GHz filters.
With the installation of the 100 GHz system described above, the Company now has
proprietary state-of-the-art systems in place for producing both 100 and 200 GHz
filters. These systems have accounted for a substantial portion of the Company's
recent research and development and capital equipment expenses. For the year
ended June 30, 2001, R&D expenses were approximately $3.2 million (up 90% from
last year), and capital equipment expenditures were approximately $3.6 million,
up more than 75% from the same period last year. With a large part of the DWDM
infrastructure currently in place, R&D and capital equipment expenditures of
this magnitude are not anticipated in the foreseeable future.

OPTICAL THIN FILMS

         200 GHZ DWDM FILTERS

         During fiscal year 2001, sales of 200 GHz DWDM filters increased by
246% over fiscal year 2000 to a record annual level, and represented 24.6% of
total revenues for fiscal year 2001.

         During the quarter ended June 30, 2001, sales of 200 GHz filters
represented 42.7% of total revenues, and increased 181% sequentially over the
third quarter of this year and increased 296% compared to the fourth quarter of
last year.

         As previously announced, subsequent to June 30, 2001, the Company's
principal customer for DWDM filters notified the Company that it had canceled
approximately $140,000 of filter orders. The Company was notified that this
action was due to the customer's excess inventories, an issue affecting
substantially all of its vendors. As a result, the Company expects shipments of
its DWDM filters during the quarter ending September 30, 2001 to be
substantially lower than the previous quarter. The Company continues to seek to
secure new and repeat filter orders from several potential customers to
counteract the resulting loss in revenue.

         100 GHZ DWDM FILTERS

         In March 2001, the Company took delivery of a new state-of-the-art 100
GHz production system. Installation and preproduction testing was completed
during the quarter ended June 30, 2001. Sample 100 GHz filters have been
provided to several potential customers, and discussions are proceeding to
obtain initial 100 GHz production orders.

DWDM FILTER TEST INSTRUMENTATION

         The Company introduced two major new products at the Optical Fiber
Communication Conference (OFC) trade show in March 2001 -- the manual Gen IIITM
DWDM Test Fixture for characterizing telecommunications filters and a fully
automated filter testing system. Both products are based on patent-pending
technology and allow greatly enhanced speed and accuracy in the measurement of
filters. Shipments of manual test fixtures represented 4.7% of total Company
revenues for fiscal year 2001. Product development is continuing on the
automated filter testing system, with initial sales anticipated during fiscal
year 2002.


                                       13



MEDICAL PRODUCTS

Sales of medical products were up 11.8% over last year, and represented 67% of
total revenues for fiscal year 2001. However, as was previously reported, the
Company's principal customer for stereo endoscopes notified the Company that it
would cease placing orders for stereo endoscopes with the Company in favor of
other sources of supply. Sales of stereo endoscopes to this customer amounted to
29% of total revenues for fiscal year 2001, and sales of all products to this
customer amounted to 41% of total revenues for fiscal year 2001.

WORKFORCE REDUCTION

The sharp reduction in demand and industry-wide excess inventory levels of
passive components has hampered the Company's ability to obtain new orders for
its DWDM filters. The Company cannot predict when significant demand for its
DWDM filters will resume. As previously announced, in August 2001, the Company
reduced its workforce by approximately 30%, or 24 employees. Along with the
workforce reduction, the Company will be reducing other discretionary expenses.
These actions together are expected to generate annual cash savings in the range
of $1.5 million to $2 million. The Company will continuously monitor marketplace
conditions to determine whether additional cost savings measures are necessary.

OUTLOOK

Noteworthy achievements during fiscal year 2001 included achieving volume
production and sales levels for 200 GHz DWDM filters, introducing new
instrumentation for low cost production testing of DWDM filters, and
introduction of several medical products to partially offset the previously
announced loss of our stereo endoscopy contract as described above.

Business prospects remain uncertain largely because of lack of visibility
concerning future spending levels for telecommunications equipment. The Company
believes that downward trends in the selling prices of DWDM filters may continue
because of existing inventory surpluses, increasing competitive pressure, and
softening demand experienced by telecommunications equipment providers.

Following the previously announced workforce reduction described above, the
Company continues to cautiously evaluate courses of action which will allow it
to retain its core DWDM capabilities in a state of readiness for the return of
DWDM filter opportunities, while conserving cash reserves and other vital
resources during this period of market slow down. The Company continues to
believe its DWDM filters and test instrumentation will be well positioned to
generate higher revenues when the overall economy and market conditions in the
telecommunications industry improve.

ITEM 7.  CONSOLIDATED FINANCIAL STATEMENTS:  The Consolidated Financial
         Statements are filed on pages 15 through 33 of this Form 10-KSB.


                                       14



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Financial Statements
as of June 30, 2001 and 2000
Together with Auditors' Report



                                       15



REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS


To Precision Optics Corporation, Inc.:

We have audited the accompanying consolidated balance sheets of Precision Optics
Corporation, Inc. (a Massachusetts corporation) and subsidiaries as of June 30,
2001 and 2000 and the related consolidated statements of operations,
stockholders' equity and cash flows for each of the three years in the period
ended June 30, 2001. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Precision Optics
Corporation, Inc. and subsidiaries as of June 30, 2001 and 2000 and the results
of their operations and their cash flows for each of the three years in the
period ended June 30, 2001, in conformity with accounting principles generally
accepted in the United States.


/s/ ARTHUR ANDERSEN LLP

Boston, Massachusetts
July 24, 2001



                                       16




PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Balance Sheets
June 30, 2001 and 2000





ASSETS                                                               2001              2000
                                                                            
Current Assets:
   Cash and cash equivalents                                     $10,530,298       $15,128,750
   Accounts receivable (net of allowance for doubtful
       accounts of approximately $155,000 and $95,000 in
       2001 and 2000, respectively)                                1,003,496           638,299
   Inventories                                                     1,524,119         1,109,511
   Prepaid expenses                                                  109,760            70,807
                                                                 -----------       -----------

         Total current assets                                     13,167,673        16,947,367
                                                                 -----------       -----------

Property and Equipment, at cost:
   Machinery and equipment                                         8,459,998         5,111,710
   Leasehold improvements                                            761,525           523,371
   Furniture and fixtures                                            125,038            94,346
   Vehicles                                                           39,486            39,486
                                                                 -----------       -----------
                                                                   9,386,047         5,768,913

   Less--Accumulated depreciation and amortization                 3,600,380         2,901,892
                                                                 -----------       -----------

                                                                   5,785,667         2,867,021
                                                                 -----------       -----------

Other Assets:
   Cash surrender value of life insurance policies                    37,065            41,292
   Patents, net                                                      229,606           229,514
                                                                 -----------       -----------

         Total other assets                                          266,671           270,806
                                                                 -----------       -----------

                                                                 $19,220,011       $20,085,194
                                                                 ===========       ===========




LIABILITIES AND STOCKHOLDERS' EQUITY                                 2001              2000
                                                                             
Current Liabilities:
   Accounts payable                                              $   584,786       $   319,096
   Accrued payroll                                                   103,392            52,116
   Accrued bonuses                                                    15,000            15,000
   Accrued professional services                                      69,051           126,866
   Accrued vacation                                                  119,143            91,930
   Accrued warranty expense                                           50,000            50,000
   Accrued income taxes                                                  912               912
   Other accrued liabilities                                          68,077             4,566
   Current portion of capital lease obligation                        51,695            95,928
                                                                 -----------       -----------
         Total current liabilities                                 1,062,056           756,414
                                                                 -----------       -----------

Capital Lease Obligation, net of current portion, and
other                                                                 68,703            88,175
                                                                 -----------       -----------

Commitments (Note 3)

Stockholders' Equity:
   Common stock, $0.01 par value--
     Authorized--20,000,000 shares
     Issued and outstanding--10,503,908 and
        10,285,158 shares at June 30, 2001 and 2000,
        respectively                                                 105,039           102,852
   Additional paid-in capital                                     27,682,657        25,094,195

   Accumulated deficit                                            (9,698,444)       (5,956,442)
                                                                 -----------       -----------

         Total stockholders' equity                               18,089,252        19,240,605
                                                                 -----------       -----------

                                                                 $19,220,011       $20,085,194
                                                                 ===========       ===========


THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED FINANCIAL
STATEMENTS.


                                       17



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Statements of Operations
for the Years Ended June 30, 2001, 2000, and 1999





                                                                    2001              2000              1999
                                                                                          
Revenues                                                        $ 4,247,828       $ 3,009,649      $ 3,028,600

Cost of Goods Sold                                                3,438,679         1,965,989        2,155,070
                                                                -----------       -----------      -----------

         Gross profit                                               809,149         1,043,660          873,530

Research and Development Expenses                                 3,215,257         1,694,409          941,234

Selling, General and Administrative Expenses                      2,103,517         1,759,886        1,608,696
                                                                -----------       -----------      -----------

         Total operating expenses                                 5,318,774         3,454,295        2,549,930
                                                                -----------       -----------      -----------

         Operating loss                                          (4,509,625)       (2,410,635)      (1,676,400)

Interest Income                                                     780,395           279,974           40,151

Interest Expense                                                    (11,860)          (24,317)         (27,154)
                                                                -----------       -----------      -----------

         Loss before provision for income taxes                  (3,741,090)       (2,154,978)      (1,663,403)

Provision for Income Taxes                                              912               912            5,642
                                                                -----------       -----------      -----------

         Net loss                                               $(3,742,002)      $(2,155,890)     $(1,669,045)
                                                                ===========       ===========      ===========

Basic and Diluted Loss per Share                                $      (.36)      $      (.26)     $      (.25)
                                                                ===========       ===========      ===========

Weighted Average Common Shares Outstanding                       10,473,348         8,379,408        6,670,308
                                                                ===========       ===========      ===========



THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED FINANCIAL
STATEMENTS.


                                       18



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Statements of Stockholders' Equity
for the Years Ended June 30, 2001, 2000 and 1999





-----------------------------------------------------------------------------------------------------------------------------
                                                                                                                  Total
                                          Number of                         Additional       Accumulated       Stockholders'
                                           Shares         Common Stock    Paid-in Capital      Deficit            Equity
-----------------------------------------------------------------------------------------------------------------------------
                                                                                                
Balance, June 30, 1998                    6,618,619         $ 66,186       $ 6,172,349       $(2,131,507)      $ 4,107,028

   Proceeds from exercise of
   options and warrants to
   purchase common stock                     65,760              658            81,012                --            81,670

   Common stock issued for
   payment of royalties                       3,216               32             7,468                --             7,500

   Costs associated with private
   placement of common stock                     --               --           (54,418)               --           (54,418)

   Net loss                                      --               --                --        (1,669,045)       (1,669,045)
                                         ----------          -------        ----------       -----------       -----------

Balance, June 30, 1999                    6,687,595           66,876         6,206,411        (3,800,552)        2,472,735

   Proceeds from exercise of
   options and warrants to
   purchase common stock                  1,808,100           18,081         3,908,836                --         3,926,917

   Net proceeds from private
   placement of common stock              1,789,463           17,895        14,978,948                --        14,996,843

   Net loss                                      --               --                --        (2,155,890)       (2,155,890)
                                         ----------          -------        ----------       -----------       -----------

Balance, June 30, 2000                   10,285,158          102,852        25,094,195        (5,956,442)       19,240,605

   Proceeds from litigation
   settlement                                    --               --         2,368,485                --         2,368,485

   Proceeds from exercise of
   options and warrants to
   purchase common stock                    218,750            2,187           236,898                --           239,085

   Costs associated with private
   placement of common stock                     --               --           (16,921)               --           (16,921)

   Net Loss                                      --               --                --        (3,742,002)       (3,742,002)
                                         ----------          -------        ----------       -----------       -----------

Balance, June 30, 2001                   10,503,908         $105,039       $27,682,657       $(9,698,444)      $18,089,252
                                         ==========         ========       ===========       ===========       ===========



THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED FINANCIAL
STATEMENTS.


                                       19



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows
for the Years Ended June 30, 2001, 2000 and 1999




                                                                            2001              2000             1999
                                                                                                  
Cash Flows from Operating Activities:
   Net loss                                                             $(3,742,002)      $(2,155,890)     $(1,669,045)
   Adjustments to reconcile net loss to net cash used in
   operating activities-
     Depreciation and amortization                                          730,500           481,569          395,829
     Deferred income taxes                                                       --                --          145,000
     Non-cash cumulative effect of  stock option liability                   32,217                --               --
     Changes in assets and liabilities-
       Accounts receivable                                                 (365,197)         (428,220)         275,991
       Inventories                                                         (414,608)         (130,227)         (29,291)
       Prepaid expenses                                                     (38,953)          (22,811)           4,374
       Accounts payable                                                     265,690           124,477           70,053
       Customer advances                                                         --                --         (116,841)
       Accrued expenses                                                      84,185            26,103         (149,723)
                                                                        -----------       -----------      -----------

         Net cash used in operating activities                           (3,448,168)       (2,104,999)      (1,073,653)
                                                                        -----------       -----------      -----------

Cash Flows from Investing Activities:
   Purchases of property and equipment                                   (3,617,134)       (1,990,527)        (379,266)
   Increase in other assets                                                 (27,877)          (36,628)         (38,770)
                                                                        -----------       -----------      -----------

         Net cash used in investing activities                           (3,645,011)       (2,027,155)        (418,036)
                                                                        -----------       -----------      -----------

Cash Flows from Financing Activities:
   Repayment of capital lease obligation                                    (95,922)         (143,588)        (114,977)
   Proceeds from litigation settlement                                    2,368,485                --               --
   Net proceeds (costs) from private placements of common stock             (16,921)       14,996,843          (54,418)
   Proceeds from exercise of stock options and warrants                     239,085         3,926,917           81,670
                                                                        -----------       -----------      -----------

         Net cash provided by (used in) financing activities              2,494,727        18,780,172          (87,725)
                                                                        -----------       -----------      -----------

Net Increase (Decrease) in Cash and Cash Equivalents                     (4,598,452)       14,648,018       (1,579,414)

Cash and Cash Equivalents, beginning of year                             15,128,750           480,732        2,060,146
                                                                        -----------       -----------      -----------

Cash and Cash Equivalents, end of year                                  $10,530,298       $15,128,750      $   480,732
                                                                        ===========       ===========      ===========

Supplemental Disclosure of Cash Flow Information:
   Cash paid during the year for-
     Interest                                                           $    11,860       $    24,317      $    27,154
                                                                        ===========       ===========      ===========
     Income taxes                                                       $       912       $       912      $       842
                                                                        ===========       ===========      ===========

Supplemental Disclosure of Noncash Investing and Financing
Activities:
   Capital lease obligation                                             $        --       $    55,837      $    72,798
                                                                        ===========       ===========      ===========
   Common stock issued for payment of royalties                         $        --       $        --      $     7,500
                                                                        ===========       ===========      ===========



THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED FINANCIAL
STATEMENTS.


                                       20



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    (a)  NATURE OF BUSINESS

         Precision Optics Corporation, Inc. (the Company) designs, manufactures
         and sells optical systems, components and thin-film coatings. The
         Company conducts business in one industry segment only and its
         customers are primarily domestic. The Company's products and services
         fall into two principal areas: (i) medical products for use by
         hospitals and physicians and (ii) advanced optical system design and
         development services and products.

         The Company has incurred significant operating losses during the last
         five fiscal years. This trend was primarily the result of the loss of
         several significant customers and the completion of several large
         nonrecurring government contracts. In fiscal 1998, the Company began
         making significant investments in research and development and capital
         purchases for new products. During fiscal 1999, the Company began
         commercial shipments of the new optical filters used in
         telecommunications systems. In August 1999 and March 2000, the Company
         raised gross proceeds of approximately $16 million of additional cash
         through the issuance of common stock (see Note 4). The Company
         believes, based on its operating and strategic plans along with the
         cash generated from the recent equity financings, that it will have
         sufficient funds to conduct operations through at least the next fiscal
         year.

    (b)  PRINCIPLES OF CONSOLIDATION

         The accompanying consolidated financial statements include the accounts
         of the Company and its two wholly owned subsidiaries. All significant
         intercompany accounts and transactions have been eliminated in
         consolidation.

    (c)  REVENUES

         In December 1999, the Securities and Exchange Commission issued Staff
         Accounting Bulletin No. 101 which establishes guidance in applying
         generally accepted accounting principles to revenue recognition in
         financial statements and is effective for the Company's fiscal 2001.
         The Company's revenue recognition practices comply with the guidance in
         the bulletin.

         Revenues for industrial and medical products sold in the normal course
         of business are recognized upon shipment. Contract revenues including
         revenues from customer-sponsored research and development contracts,
         are recognized under the percentage-of-completion method. The
         percentage of completion is determined by computing the percentage of
         the actual cost of work performed to the anticipated total contract
         costs. When the estimate on a contract indicates a loss, the Company's
         policy is to record the entire loss in the current period.

    (d)  CASH AND CASH EQUIVALENTS

         The Company includes in cash equivalents all highly liquid investments
         with original maturities of three months or less at the time of
         acquisition. Cash equivalents consist primarily of overnight repurchase
         agreements and United States Treasury bills.


                                       21



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


    (e)  INVENTORIES

         Inventories are stated at the lower of cost (first-in, first-out) or
         market and include material, labor and manufacturing overhead. The
         components of inventories at June 30, 2001 and 2000 are as follows:




                                       2001             2000
                                               
         Raw material              $  777,269        $  686,856
         Work-in-progress             462,517           241,686
         Finished goods               284,333           180,969
                                   ----------        ----------

                                   $1,524,119        $1,109,511
                                   ==========        ==========


    (f)  DEPRECIATION AND AMORTIZATION

         The Company provides for depreciation and amortization by charges to
         operations, using the straight-line and declining-balance methods,
         which allocate the cost of property and equipment over the following
         estimated useful lives:




                                      ESTIMATED USEFUL
           ASSET CLASSIFICATION             LIFE
                                    
         Machinery and equipment       5-7 years
         Leasehold improvements        Life of lease
         Furniture and fixtures        5 years
         Vehicles                      3 years



    (g)  SIGNIFICANT CUSTOMERS AND CONCENTRATION OF CREDIT RISK

         Statement of Financial Accounting Standards (SFAS) No. 105, DISCLOSURE
         OF INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK
         AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK, requires
         disclosure of any significant off-balance sheet and credit risk
         concentrations. Financial instruments that subject the Company to
         credit risk consist primarily of cash and cash equivalents and trade
         accounts receivable. The Company places its investments in highly rated
         financial institutions. The Company has not experienced any losses on
         these investments to date. At June 30, 2001 and 2000, receivables from
         the Company's largest customer were approximately 59% and 55% of the
         total accounts receivable, respectively. No other customers accounted
         for more than 10% of the Company's receivables as of June 30, 2001 and
         2000. The Company has not experienced any material losses related to
         accounts receivable from individual customers.

         Revenues from the Company's two largest customers were approximately
         41% and 18%, respectively, of total revenues for the year ended June
         30, 2001. Revenues from the Company's two largest customers were
         approximately 46% and 11% of total revenues for the year ended June 30,
         2000. Revenues from the Company's largest customer were approximately
         37% of total revenues for the year ended June 30, 1999. No other
         customers accounted for more than 10% of the Company's revenues in any
         of the three years ended June 30, 2001.


                                       22



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


    (h)  LOSS PER SHARE

         The Company calculates earnings per share according to SFAS No. 128,
         EARNINGS PER SHARE. Basic loss per share is computed by dividing net
         loss by the weighted average number of shares of common stock
         outstanding during the period. For each of the three years in the
         period ended June 30, 2001, the effect of stock options and warrants
         was antidilutive; therefore, they were not included in the computation
         of diluted loss per share. The number of shares that were excluded from
         the computation, as their effect would be antidilutive, were 1,232,598,
         1,396,698 and 1,605,500 during fiscal 2001, 2000 and 1999,
         respectively.

    (i)  STOCK-BASED COMPENSATION

         The Company accounts for its stock-based compensation under Accounting
         Principles Board Opinion No. 25, ACCOUNTING FOR STOCK ISSUED TO
         EMPLOYEES. SFAS No. 123, ACCOUNTING FOR STOCK-BASED COMPENSATION,
         establishes a fair-value-based method of accounting for stock-based
         compensation plans. The Company has adopted the disclosure-only
         alternative under SFAS No. 123, which requires the disclosure of the
         pro forma effects on earnings and earnings per share as if the
         accounting prescribed by SFAS No. 123 had been adopted, as well as
         certain other information. [See Note 4 (d)].

    (j)  FOREIGN CURRENCY TRANSLATION

         The Company translates certain accounts and financial statements of its
         foreign subsidiary in accordance with SFAS No. 52, FOREIGN CURRENCY
         TRANSLATION. The functional currency of the Company's foreign
         subsidiary is the United States dollar. Accordingly, translation gains
         or losses are reflected in the accompanying consolidated statements of
         operations and have not been significant.

    (k)  OTHER ASSETS

         Patents are carried at cost, less accumulated amortization of
         approximately $232,000 and $200,000 at June 30, 2001 and 2000,
         respectively. Such costs are amortized using the straight-line method
         over the shorter of their legal or estimated useful lives, generally
         five to ten years.

    (l)  FINANCIAL INSTRUMENTS

         SFAS No. 107, DISCLOSURE ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS,
         requires disclosures about the fair value of financial instruments.
         Financial instruments consist principally of accounts receivable,
         accounts payable and capital lease obligations. The estimated fair
         value of these financial instruments approximates their carrying value.

    (m)  LONG-LIVED ASSETS

         The Company accounts for long-lived assets in accordance with SFAS No.
         121, ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS AND FOR
         LONG-LIVED ASSETS TO BE DISPOSED OF. The Company


                                       23



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


         periodically reviews its long-lived assets for potential impairment.
         The Company assesses the future useful life of these assets, primarily
         property, plant and equipment whenever events or changes in
         circumstances indicate that the current useful life has diminished. The
         Company considers the future undiscounted cash flows of these assets in
         assessing their recoverability. If impairment has occurred, any excess
         of carrying value over fair value is recorded as a loss. As of June 30,
         2001 and 2000, the Company has determined that no material adjustment
         to the carrying value of its long-lived assets was required.

    (n)  WARRANTY COSTS

         The Company does not incur future performance obligations in the normal
         course of business other than providing a standard one-year warranty on
         materials and workmanship to its customers. The Company provides for
         estimated warranty costs at the time product revenue is recognized.
         Warranty costs were $26,219, $11,221, and $24,459 for the years ended
         June 30, 2001, 2000, and 1999, respectively.

    (o)  RESEARCH AND DEVELOPMENT

         Research and development expenses are charged to operations as
         incurred.

    (p)  COMPREHENSIVE INCOME

         SFAS No. 130 requires disclosure of all components of comprehensive
         income on an annual and interim basis. Comprehensive income is defined
         as the change in equity of a business enterprise during a period from
         transactions and other events and circumstances from nonowners sources.
         The Company's comprehensive loss for the years ended June 30, 2001,
         2000 and 1999 was equal to its net loss for the same periods.

    (q)  ACCOUNTING FOR DERIVATIVE INSTRUMENTS

         In September 2000, the Emerging Issues Task Force issued EITF 00-19,
         ACCOUNTING FOR DERIVATIVE FINANCIAL INSTRUMENTS INDEXED TO, AND
         POTENTIALLY SETTLED IN, A COMPANY'S OWN STOCK, which requires
         freestanding contracts that are settled in a company's own stock,
         including common stock options and warrants, to be designated as an
         equity instrument, asset or a liability. Under the provisions of EITF
         00-19, a contract designated as an asset or a liability must be carried
         at fair value, with any changes in fair value recorded in the results
         of operations. A contract designated as an equity instrument must be
         included within equity, and no fair value adjustments are required. In
         accordance with EITF 00-19, the Company has determined that outstanding
         options as of June 30, 2001 to purchase 25,000 shares of the Company's
         common stock should be reclassified outside of stockholders' equity.

         Under the transition rules of EITF 00-19, effective June 30, 2001, the
         Company has recorded these options as a liability at fair value with a
         required adjustment included as a cumulative adjustment in its results
         of operations for the fiscal year ended June 30, 2001. After June 30,
         2001, the outstanding options are recorded at fair value with any
         changes in the fair value included in the results of operations.
         Pursuant to EITF 00-19, as of June 30, 2001, the Company has recorded
         an option liability totaling approximately $32,000 which is included
         under "Capital Lease Obligations and Other" in the accompanying balance
         sheet and the corresponding immaterial cumulative


                                       24



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


         adjustment for the same amount which is included in "Selling, General
         and Administrative Expenses" in the accompanying statement of
         operations.

    (r)  USE OF ESTIMATES

         The preparation of financial statements in conformity with accounting
         standards generally accepted in the United States requires management
         to make estimates and assumptions that affect the reported amounts of
         assets and liabilities and disclosure of contingent assets and
         liabilities at the date of the financial statements and the reported
         amounts of revenues and expenses during the reporting period. Actual
         results could differ from those estimates.

    (s)  RECENT ACCOUNTING PRONOUNCEMENTS

         In June 1999, the Financial Accounting Standards Board (FASB) issued
         Statement of Financial Accounting Standards ("SFAS") No. 137,
         ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - DEFERRAL
         OF THE EFFECTIVE DATE OF FASB STATEMENT NO. 133, which defers the
         effective date of SFAS No. 133 to all fiscal quarters of all fiscal
         years beginning after June 15, 2000. SFAS No. 133, ACCOUNTING FOR
         DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES, establishes accounting
         and reporting standards for derivative instruments, including certain
         derivative instruments embedded in other contracts, and for hedging
         activities. It requires entities to recognize all derivatives as either
         assets or liabilities in the statement of financial position and
         measure those instruments at fair value. The adoption of this new
         accounting standard did not have a material impact on the Company's
         financial statements.

         In July 2001, the Financial Accounting Standards Board (FASB) issued
         SFAS No. 141, BUSINESS Combinations. SFAS No. 141 requires all business
         combinations initiated after June 30, 2001 to be accounted for using
         the purchase method. This statement is effective for all business
         combinations initiated after June 30, 2001.

         In July 2001, the FASB issued SFAS No. 142, GOODWILL AND OTHER
         INTANGIBLE ASSETS. This statement applies to goodwill and intangible
         assets acquired after June 30, 2001, as well as goodwill and intangible
         assets previously acquired. Under this statement goodwill as well as
         certain other intangible assets, determined to have an infinite life,
         will no longer be amortized; instead these assets will be reviewed for
         impairment on a periodic basis. This statement is effective for the
         Company for the first quarter in the fiscal year ended June 2002. The
         adoption of this new accounting standard is not expected to have a
         material impact on the Company's financial statements.


                                       25



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


(2) CAPITAL LEASE OBLIGATION

At June 30, 2001, future minimum lease payments under capital lease obligations
are as follows:




                                                              AMOUNT
                                                           
Fiscal year-
   2002                                                       $57,580
   2003                                                        34,450
   2004                                                         3,488
                                                              -------

         Total minimum lease payments                          95,518

Amount representing interest                                    7,337
                                                              -------

         Present value of minimum lease payments               88,181

Less--Current portion                                          51,695
                                                              -------

                                                              $36,486
                                                              =======


Capital leases are secured by all assets of the Company under a security
agreement.

(3) COMMITMENTS

    (a)  RELATED PARTY TRANSACTIONS

         The Company leases one of its facilities from a corporation owned by an
         officer of the Company. The lease terminated in December 1999 and
         required lease payments of $9,000 per month. The Company is currently a
         tenant at will paying lease payments of $9,000 a month.

         The Company paid fees to a director of approximately $24,000, $45,000,
         and $60,000 for services performed during fiscal 2001, 2000 and 1999,
         respectively. Another director is a former partner in a law firm that
         has performed legal services for the Company during fiscal 2001, 2000
         and 1999 of approximately $320,000, $253,000, and $125,000,
         respectively. Another director is the owner of a company that provided
         approximately $20,000, $67,000, and $30,000 in software and consulting
         services to the Company during fiscal 2001, 2000 and 1999,
         respectively.

    (b)  OPERATING LEASE COMMITMENTS

         In August 2000, the Company entered into a new facility lease for
         future development and manufacturing purposes. The lease includes a
         yearly escalation clause and provides for the option to renew at the
         end of the term. Lease commitments began in November 2000 and include
         estimated-shared costs. The lease expires in October 2005.


                                       26



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


         The Company has entered into operating leases for its office space and
         equipment that expire at various dates through fiscal year 2006. Total
         future minimum rental payments under all operating leases are
         approximately as follows:




                                  AMOUNT
                              
         Fiscal year-
            2002                 $174,000
            2003                  159,000
            2004                  159,000
            2005                  147,000
            2006                   49,000
                                 --------
                                 $688,000
                                 ========


       Rent expense on operating leases was approximately $258,000, $158,000,
       and $188,000 for the years ended June 30, 2001, 2000 and 1999,
       respectively.

(4) STOCKHOLDERS' EQUITY

    (a)  AUTHORIZED COMMON STOCK

         During fiscal 2000, the Board of Directors voted to increase the number
         of authorized shares of common stock from 10,000,000 to 20,000,000
         shares.

    (b)  PRIVATE PLACEMENTS

         In August 1999, the Company completed a private placement of 1,000,000
         shares of common stock with gross proceeds of $1,062,500 before related
         expenses of approximately $38,000. In conjunction with this offering,
         the purchasers were issued warrants to acquire 1,000,000 shares of
         common stock at an exercise price of $1.125 per share. The warrants are
         immediately exercisable and expire in August 2004.

         In March 2000, the Company completed a private placement of 789,463
         shares of common stock with gross proceeds of $15 million before
         related expenses of approximately $1,045,000. In conjunction with this
         offering, the purchasers were issued warrants to acquire 465,798 shares
         of common stock at a weighted average exercise price of $26.73 per
         share. The warrants are immediately exercisable and expire in March
         2005.

    (c)  WARRANTS

         During fiscal 2000, warrants with an exercise price of $4.00 per share
         for 500,000 shares and warrants with an exercise price of $1.125 per
         share for 789,500 shares were exercised, resulting in proceeds to the
         Company of $2,888,188. During fiscal year 2001, warrants with an
         exercise price of $1.125 per share for 210,500 shares were exercised
         resulting in proceeds to the Company of $236,813. As of June 30, 2001,
         the Company had 465,798 fully-exercisable warrants outstanding at a
         weighted average exercise price of $26.73.


                                       27



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


    (d)  STOCK OPTIONS

         During 1989, the stockholders approved a stock option plan (the 1989
         Plan) for key employees. The 1989 Plan, as amended, authorizes the
         grant of options of up to 1,110,000 shares of the Company's common
         stock at an exercise price not less than 100% of the fair market value
         per share at the date of grant. Options granted are exercisable for a
         period determined by the Board of Directors, not to exceed 10 years
         from the date of grant.

         During fiscal 1998, the stockholders approved an incentive plan (the
         1997 Incentive Plan), which provides eligible participants (certain
         employees, directors, consultants, etc.) the opportunity to receive a
         broad variety of equity based and cash awards. A total of 1,200,000
         shares of common stock have been reserved for issuance under the 1997
         Incentive Plan. Upon the adoption of the 1997 Incentive Plan, no new
         awards will be granted under the 1989 Plan. At June 30, 2001, 591,350
         shares of common stock were available for future grants under the 1997
         Incentive Plan.

         The following is a summary of transactions in the plans for the three
         years ended June 30, 2001:




                                                                                     WEIGHTED
                                                                                     AVERAGE
                                                    NUMBER OF    OPTION PRICE PER    EXERCISE
                                                     SHARES           SHARE           PRICE
                                                                             
          Options outstanding, June 30, 1998         992,500       $1.375-3.844       $ 2.46
             Granted                                  25,000              1.312         1.31
             Canceled                                (56,000)        3.00-3.844         3.09
                                                    --------       ------------       ------

          Options outstanding, June 30, 1999         961,500        1.312-3.844         2.39
             Granted                                 215,000          1.00-5.00         3.91
             Exercised                              (441,100)        1.00-3.844         3.51
             Canceled                                (81,500)        1.00-3.844         2.55
                                                    --------       ------------       ------

          Options outstanding, June 30, 2000         653,900          1.00-5.00         3.03
              Granted                                 66,900         2.50-12.50         5.65
              Exercised                               (8,250)        1.00-1.563         1.36
              Canceled                                  (750)             3.844        3.844
                                                    --------       ------------       ------

          Options outstanding, June 30, 2001         711,800       $ 1.00-12.50       $ 2.73
                                                    ========       ============       ======

          Options exercisable, June 30, 2001         551,125       $ 1.00-12.50       $ 2.95
                                                    ========       ============       ======

          Options exercisable, June 30, 2000         386,400       $  1.00-5.00       $ 2.42
                                                    ========       ============       ======

          Options exercisable, June 30, 1999         663,000       $1.312-3.844       $ 2.39
                                                    ========       ============       ======



                                       28



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


         The following table summarizes information about stock options
         outstanding and exercisable at June 30, 2001:




                             OPTIONS OUTSTANDING                                        OPTIONS EXERCISABLE
  -----------------------------------------------------------------------       ------------------------------------
                                         Weighted
                                          Average
   Range of Exercise        Options      Remaining           Weighted                 Options       Weighted Average
         Prices           Outstanding   Contractual      Average Exercise           Exercisable      Exercise Price
                                           Life               Price
                                                                                        
     $1.00 - $1.31           162,750    4.73 years            $1.31                    142,750          $1.35

      1.50 - 2.19            130,000    5.76 years             1.83                    130,000           1.83

      2.50 - 2.75             26,250    8.72 years             2.56                     11,250           2.64

      3.84 - 5.50            380,900    7.51 years             4.41                    264,150           4.26

         12.50                11,900    9.17 years            12.50                      2,975          12.50
                             -------                                                   -------

     $1.00 - $12.50          711,800    5.55 years            $2.73                    551,125          $2.95
                             =======                                                   =======


         In addition, the Company has granted options outside the plans,
         primarily to directors and consultants at 100% of the fair market value
         per share at the date of grant. The following is a summary of all
         transactions outside the plans:




                                                                                    WEIGHTED
                                                                                    AVERAGE
                                                    NUMBER OF    OPTION PRICE       EXERCISE
                                                     SHARES       PER SHARE          PRICE
                                                                             
         Options outstanding, June 30, 1998           154,000    $ 0.50-5.69          $1.43
            Exercised                                 (10,000)          0.50           0.50
                                                      -------    -----------          -----

         Options outstanding, June 30, 1999           144,000      0.50-5.69           1.50
            Exercised                                 (77,500)     0.50-5.69           1.75
                                                      -------    -----------          -----

         Options outstanding, June 30, 2000            66,500     0.50-1.375           1.20
             Canceled                                 (11,500)          0.50           0.50
                                                      =======    ===========          =====

         Options outstanding, June 30, 2001            55,000    $1.30-1.375          $1.35
                                                      =======    ===========          =====

         Options exercisable, June 30, 2001            55,000    $1.30-1.375          $1.35
                                                      =======    ===========          =====

         Options exercisable, June 30, 2000            66,500    $0.50-1.375          $1.20
                                                      =======    ===========          =====

         Options exercisable, June 30, 1999           132,000    $ 0.50-5.69          $1.50
                                                      =======    ===========          =====



                                       29



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


         The Company has computed the pro forma disclosures required under SFAS
         No. 123 for all stock options granted in fiscal 2001, 2000 and 1999
         using the Black-Scholes option pricing model prescribed by SFAS No.
         123.

         The assumptions used and the weighted average information for each of
         the three years in the period ended June 30, 2001 are as follows:




                                                               YEAR ENDED
                                                ---------------------------------------
                                                     2001          2000           1999
                                                                    
          Risk-free interest rates                   5.52%         6.30%          4.54%
          Expected dividend yield                       --            --             --
          Expected lives                           7 years       7 years        7 years
          Expected volatility                         123%           99%            99%
          Weighted average fair value
             of grants                               $5.18         $3.32          $1.10
          Weighted-average remaining
             contractual life of options
             outstanding                        5.55 years    7.11 years     7.28 years



         The effect of applying SFAS No. 123 would be as follows:




                                                               YEAR ENDED
                                             ----------------------------------------------
                                                  2001           2000            1999
                                                                      
         Net loss-
            As reported                      $(3,742,002)     $(2,155,890)     $(1,669,045)
            Pro forma                        $(4,113,886)     $(2,478,314)     $(2,068,728)

         Net loss per share-
            As reported, basic and diluted   $      (.36)     $      (.26)     $      (.25)
            Pro forma, basic and diluted     $      (.39)     $      (.30)     $      (.31)



(5) INCOME TAXES

         The Company accounts for income taxes in accordance with SFAS No. 109,
         ACCOUNTING FOR INCOME TAXES, whereby a deferred tax asset or liability
         is measured using currently enacted tax rates applied to any temporary
         differences between the financial statement and tax bases of assets and
         liabilities.


                                       30



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


     The provision for income taxes in the accompanying consolidated statements
     of operations consists of the following for the three years ended June 30,
     2001:




                        2001              2000              1999
                                                 
Current-
   Federal              $ --              $ --            $(136,346)
   State                 912               912                  912
   Foreign                --                --               (3,924)
                        ----              ----            ---------

                         912               912             (139,358)
                        ----              ----            ---------
Deferred-
   Federal                --                --              123,000
   State                  --                --               22,000
                        ----              ----            ---------

                          --                --              145,000
                        ----              ----            ---------

                        $912              $912            $   5,642
                        ====              ====            =========


     A reconciliation of the federal statutory rate to the Company's effective
     tax rate for the three years ended June 30, 2001 is as follows:




                                                   2001          2000          1999
                                                                     
Income tax benefit at federal statutory rate      (34.0)%       (34.0)%       (34.0)%

Increase (decrease) in tax resulting from-
   Change in valuation allowance (net of
     valuation allowance of approximately
     $16,000 and $1,900,000 related to
     exercise of stock options during
     fiscal 2001 and 2000, respectively)           38.1          31.6          31.3
   Other                                           (4.1)          2.4           3.0
                                                 ------         -----         -----

         Effective tax rate                         0.0%          0.0%          0.3%
                                                 ======         =====         =====



                                       31



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


     The components of the net deferred tax asset at June 30, 2001 and 2000 are
     approximately as follows:




                                                      2001              2000
                                                              
Net operating loss carryforward                   $ 3,795,000       $ 3,446,000
Reserves and accruals not yet deducted for
   tax purposes                                     1,784,000           618,000
Other temporary differences                          (178,000)         (105,000)
                                                  -----------       -----------

                                                    5,401,000         3,959,000

Valuation allowance                                (5,401,000)       (3,959,000)
                                                  -----------       -----------

         Net deferred tax asset                   $        --       $        --
                                                  ===========       ===========


     The Company has provided a valuation allowance to reduce the net deferred
     tax asset to an amount the Company believes it is "more likely than not" to
     be realized. The valuation allowance increased in fiscal 2001 primarily due
     to the generation of a net operating loss carryforward. Approximately
     $1,916,000 of the valuation allowance at June 30, 2001 related to the
     exercise of stock options will be allocated to stockholders' equity when
     recognized. As of June 30, 2001, the Company has net operating loss
     carryforwards for U.S. federal income taxes of approximately $11,000,000 of
     which approximately $85,000 expires in 2012, approximately $1,500,000
     expires in 2013, approximately $1,500,000 expires in 2019, approximately
     $7,000,000 expires in 2020, and approximately $915,000 expires in 2021.
     Pursuant to the Tax Reform Act of 1986, the utilization of net operating
     loss carryforwards for tax purposes may be subject to an annual limitation
     if a cumulative change or ownership of more than 50% occurs over a
     three-year period. As a result of the Company's recent stock offerings,
     such a change in ownership may have occurred. In the event that the Company
     has had a change in ownership, as defined, the utilization of substantially
     all of the Company's net operating loss carryforwards may be restricted.

(6)  PROFIT SHARING PLAN

     The Company has a defined contribution profit sharing plan that covers all
     eligible employees. No employer contributions were made in fiscal 2001,
     2000 or 1999.

(7)  SEGMENT REPORTING

     SFAS No. 131 establishes standards for reporting information regarding
     operating segments in annual financial statements and requires selected
     information for those segments to be presented in interim financial reports
     issued to stockholders. SFAS No. 131 also establishes standards for related
     disclosures about products and services and geographic areas. Operating
     segments are identified as components of an enterprise about which separate
     discrete financial information is available for evaluation by the chief
     operating decision maker, or decision making group, in making decisions
     about how to allocate resources and assess performance. The Company's chief
     decision-maker, as defined under SFAS No. 131, is the Chief Executive
     Officer. To date, the Company has viewed its operations and manages its
     business as principally one segment. For all periods presented, over 90% of
     the Company's sales have been to customers in the United States.


                                       32



PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Continued)


(8)  LITIGATION SETTLEMENT

     In July 2000, the Company reached an agreement to settle certain claims of
     the Company arising under Section 16(b) of the Securities Exchange Act of
     1934 involving certain investment funds and their respective investment
     advisers, and to settle and dismiss with prejudice a related shareholder
     lawsuit brought against the funds and their advisers. One of the defendants
     in this action is a principal of the funds and is also a director of the
     Company. Under the agreement, the investment funds have paid the Company a
     total of $2,650,000 to resolve claims of "short-swing" trading profits
     allegedly made in violation of Section 16(b). This settlement and dismissal
     with prejudice of the shareholder lawsuit was approved by the United States
     District Court for the Southern District of New York in August 2000.

     After deducting estimated legal expenses, the net proceeds of the
     settlement of approximately $2,370,000 was credited to Additional Paid-In
     Capital in the Company's Consolidated Balance Sheet in the quarter ending
     September 30, 2000.


ITEM 8.   CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
          FINANCIAL DISCLOSURE: None.

PART III

ITEM 9.   DIRECTORS, EXECUTIVE OFFICERS, AND CONTROL PERSONS; COMPLIANCE
          WITH SECTION 16(A) OF THE EXCHANGE ACT: The Company will furnish to
          the Securities and Exchange Commission a definitive Proxy Statement
          (the "Proxy Statement") not later than 120 days after the close of its
          fiscal year ended June 30, 2000. The information required by this item
          is incorporated herein by reference to the Proxy Statement.

ITEM 10.  EXECUTIVE COMPENSATION: The information required by this item is
          incorporated herein by reference to the Proxy Statement.

ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT: The
          information required by this item is incorporated herein by reference
          to the Proxy Statement.

ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS: The information
          required by this item is incorporated herein by reference to the Proxy
          Statement.

ITEM 13.  EXHIBITS AND REPORTS ON FORM 8-K:

          (a)          EXHIBITS.
                       --------
                       The exhibits listed below are filed with or
                       incorporated by reference in this report.

          3.1          Articles of Organization of the Company, as amended and
                       corrected(1)
          3.2          By-laws of Precision Optics Corporation, Inc.(2)
          4.1          Specimen common stock certificate(3)


                                       33



         4.2      Registration Rights Agreement dated as of March 17, 2000 by
                  and among the Company and the Initial Investors as defined
                  therein(4)
         4.3      Registration Rights Agreement dated as of June 30, 1998 by and
                  among the Company, Special Situations Private Equity Fund,
                  L.P. and Special Situations Technology Fund, L.P.(5)
         4.4      Registration Rights Agreement dated as of August 5, 1999 by
                  and among the Company, Special Situations Cayman Funds, L.P.,
                  Special Situations Fund III, L.P., Special Situations Private
                  Equity Fund, L.P. and Special Situations Technology Fund, L.P.
                  (6)
         4.5      Form of Stock Purchase Warrant dated March 17, 2000 issued to
                  each investor in March 17, 2000 private placement transaction
                  (4)
         4.6      Warrant No. 1 dated March 17, 2000 issued to First Security
                  Van Kasper(4)
         4.7      Warrant No. 2 dated March 17, 2000 issued to First Security
                  Van Kasper(4)
         4.8      Common Stock Purchase Warrant dated August 5, 1999 issued to
                  Special Situations Cayman Fund, L.P.(6)
         4.9      Common Stock Purchase Warrant dated August 5, 1999 issued to
                  Special Situations Technology Fund, L.P.(6)
         10.1     Lease dated June 29, 1984 between the Company and Equity,
                  First Amendment to Commercial Lease dated June 25, 1990, and
                  letter agreement dated June 25, 1990 renewing such lease(3)
         10.2     Second Amendment to Commercial Lease between the Company and
                  Equity dated December 9, 1994(7)
         10.3     Precision Optics Corporation, Inc. 1989 Stock Option Plan
                  amended to date (the "Plan")(8)
         10.4     Three separate life insurance policies on the life of Richard
                  E. Forkey(3)
         10.5     Master Lease Finance Agreement dated November 3, 1993 between
                  the Company and BancBoston Leasing(8)
         10.6     Lease dated March 1, 1999, between the Company and Philip A.
                  Wood, as executor of the Estate of Alma L. Wood and as devisee
                  under the Will of Alma L. Wood; Martha A. Mount, devisee under
                  the Will of Alma L. Wood; and Nancy E. Popinchalk, devisee
                  under the Will of Alma L. Wood for 21 Pleasant Street,
                  Gardner, Massachusetts(6)
         10.7     Precision Optics Corporation, Inc. 1997 Incentive Plan.(5)
         10.8     Stock Subscription Agreement dated as of June 30, 1998 by and
                  among the Company, Special Situations Private Equity Fund,
                  L.P. and Special Situations Technology Fund, L.P.(5)
         10.9     Stock Subscription Agreement dated as of August 5, 1999 by and
                  among the Company, Special Situations Cayman Funds, L.P.,
                  Special Situations Fund III, L.P., Special Situations Private
                  Equity Fund, L.P. and Special Situations Technology Fund, L.P.
                  (6)
         10.10    Securities Purchase Agreement dated as of March 13, 2000 by
                  and among the Company and the Purchasers as defined therein
                  (excluding exhibits)(4)
         10.11    Commercial Lease dated August 23, 2000 between the Company and
                  Urquhart Family LLC(9)
         21       Subsidiaries of Precision Optics Corporation, Inc.(7)
         23       Consent of Arthur Andersen
         99       Important Factors Regarding Forward-Looking Statements

(1) Incorporated herein by reference to the Company's Registration Statement on
Form S-8 POS (No. 333-89989).


                                       34




(2) Incorporated herein by reference to the Company's 1991 Annual Report on Form
10-KSB No. 001-10647.

(3) Incorporated herein by reference to the Company's Registration Statement on
Form S-18 (No. 33-36710-B).

(4) Incorporated herein by reference to the Company's Registration Statement on
Form S-3 (No. 333-35884).

(5) Incorporated herein by reference to the Company's 1998 Annual Report on Form
10-KSB No. 001-10647.

(6) Incorporated herein by reference to the Company's 1999 Annual Report on Form
10-KSB No. 001-10647.

(7) Incorporated herein by reference to the Company's 1996 Annual Report on Form
10-KSB No. 001-10647.

(8) Incorporated herein by reference to the Company's 1994 Annual Report on Form
10-KSB No. 001-10647.

(9) Incorporated herein by reference to the Company's 2000 Annual Report on Form
10-KSB No. 001-10647.


(b)        REPORTS ON FORM 8-K.

           The Company filed one Current Report on Form 8-K during the quarter
           ended June 30, 2001 as follows - On May 10, 2001, the Company
           reported a press release issued May 9, 2001, reporting its operating
           results for the quarter ended March 31, 2001.


                                       35




                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date:  September 20, 2001                 PRECISION OPTICS CORPORATION, INC.


                                          By: /s/ Richard E. Forkey
                                              ----------------------------------
                                              Richard E. Forkey
                                              Chairman of the Board,
                                              Chief Executive Officer, President
                                              and Treasurer

In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.


By: /s/ Richard E. Forkey                By: /s/ Jack P. Dreimiller
    ------------------------                 -----------------------------------
    Richard E. Forkey                        Jack P. Dreimiller
    President, Treasurer and                 Senior Vice President, Finance,
    Director (principal                      Chief Financial Officer and Clerk
    executive officer)                       (principal financial and accounting
                                             officer)

Date:  September 20, 2001                Date:  September 19, 2001


By: /s/ Joel R. Pitlor                   By: /s/ Edward A. Benjamin
    ------------------------                 -----------------------------------
     Joel R. Pitlor                          Edward A. Benjamin
     Director                                Director

Date:  September 19, 2001                Date:  September 20, 2001


By: /s/ Robert R. Shannon                By: /s/ H. Angus Macleod
    ------------------------                 ----------------------------------
    Robert R. Shannon                        H. Angus Macleod
    Director                                 Director

Date:  September 19, 2001                Date:  September 19, 2001


By: /s/ Austin W. Marxe
    -------------------
    Austin W. Marxe
    Director

Date:  September 21, 2001


                                       36




    INDEX TO EXHIBITS

         3.1      Articles of Organization of the Company, as amended and
                  corrected(1)
         3.2      By-laws of Precision Optics Corporation, Inc.(2)
         4.1      Specimen common stock certificate(3)
         4.2      Registration Rights Agreement dated as of March 17, 2000 by
                  and among the Company and the Initial Investors as defined
                  therein(4)
         4.3      Registration Rights Agreement dated as of June 30, 1998 by and
                  among the Company, Special Situations Private Equity Fund,
                  L.P. and Special Situations Technology Fund, L.P.(5)
         4.4      Registration Rights Agreement dated as of August 5, 1999 by
                  and among the Company, Special Situations Cayman Funds, L.P.,
                  Special Situations Fund III, L.P., Special Situations Private
                  Equity Fund, L.P. and Special Situations Technology Fund, L.P.
                  (6)
         4.5      Form of Stock Purchase Warrant dated March 17, 2000 issued to
                  each investor in March 17, 2000 private placement transaction
                  (4)
         4.6      Warrant No. 1 dated March 17, 2000 issued to First Security
                  Van Kasper(4)
         4.7      Warrant No. 2 dated March 17, 2000 issued to First Security
                  Van Kasper(4)
         4.8      Common Stock Purchase Warrant dated August 5, 1999 issued to
                  Special Situations Cayman Fund, L.P.(6)
         4.9      Common Stock Purchase Warrant dated August 5, 1999 issued to
                  Special Situations Technology Fund, L.P.(6)
         10.1     Lease dated June 29, 1984 between the Company and Equity,
                  First Amendment to Commercial Lease dated June 25, 1990, and
                  letter agreement dated June 25, 1990 renewing such lease(3)
         10.2     Second Amendment to Commercial Lease between the Company and
                  Equity dated December 9, 1994(7)
         10.3     Precision Optics Corporation, Inc. 1989 Stock Option Plan
                  amended to date (the "Plan")(8)
         10.4     Three separate life insurance policies on the life of Richard
                  E. Forkey(3)
         10.5     Master Lease Finance Agreement dated November 3, 1993 between
                  the Company and BancBoston Leasing(8)
         10.6     Lease dated March 1, 1999, between the Company and Philip A.
                  Wood, as executor of the Estate of Alma L. Wood and as devisee
                  under the Will of Alma L. Wood; Martha A. Mount, devisee under
                  the Will of Alma L. Wood; and Nancy E. Popinchalk, devisee
                  under the Will of Alma L. Wood for 21 Pleasant Street,
                  Gardner, Massachusetts6 10.7 Precision Optics Corporation,
                  Inc. 1997 Incentive Plan(5)
         10.8     Stock Subscription Agreement dated as of June 30, 1998 by and
                  among the Company, Special Situations Private Equity Fund,
                  L.P. and Special Situations Technology Fund, L.P.(5)
         10.9     Stock Subscription Agreement dated as of August 5, 1999 by and
                  among the Company, Special Situations Cayman Funds, L.P.,
                  Special Situations Fund III, L.P., Special Situations Private
                  Equity Fund, L.P. and Special Situations Technology Fund, L.P.
                  (6)
         10.10    Securities Purchase Agreement dated as of March 13, 2000 by
                  and among the Company and the Purchasers as defined therein
                  (excluding exhibits)(4)
         10.11    Commercial Lease dated August 23, 2000 between the Company and
                  Urquhart Family LLC(9)
         21       Subsidiaries of Precision Optics Corporation, Inc.(7)
         23       Consent of Arthur Andersen
         99       Important Factors Regarding Forward-Looking Statements


                                       37




(1) Incorporated herein by reference to the Company's Registration Statement on
Form S-8 POS (No. 333- 89989).

(2) Incorporated herein by reference to the Company's 1991 Annual Report on Form
10-KSB No. 001-10647.

(3) Incorporated herein by reference to the Company's Registration Statement on
Form S-18 (No. 33-36710-B).

(4) Incorporated herein by reference to the Company's Registration Statement on
Form S-3 (No. 333-35884).

(5) Incorporated herein by reference to the Company's 1998 Annual Report on Form
10-KSB No. 001-10647.

(6) Incorporated herein by reference to the Company's 1999 Annual Report on Form
10-KSB No. 001-10647.

(7) Incorporated herein by reference to the Company's 1996 Annual Report on Form
10-KSB No. 001-10647.

(8) Incorporated herein by reference to the Company's 1994 Annual Report on Form
10-KSB No. 001-10647.

(9) Incorporated herein by reference to the Company's 2000 Annual Report on Form
10-KSB No. 001-10647.


                                       38

EX-23

                                                                      Exhibit 23



                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS


As independent public accountants, we hereby consent to the incorporation of our
report dated July 24, 2001 included in this Form 10-KSB, into the Company's
previously filed Registration Statements on Form S-3, File Numbers 333-35884,
333-87977 and 333-66297 and on Form S-8, File Numbers 333-89989, 333-94125 and
33-72108.

                                                     /s/ Arthur Andersen LLP

                                                     ARTHUR ANDERSEN LLP

Boston, Massachusetts
September 20, 2001

EX-99

                                   EXHIBIT 99


                       PRECISION OPTICS CORPORATION, INC.
             IMPORTANT FACTORS REGARDING FORWARD-LOOKING STATEMENTS

    In our annual report on Form 10-KSB for the fiscal year ended June 30, 2001
and from time to time in public statements made by our management, we have made
and will continue to make forward-looking statements about our business,
including predictions about our future financial performance. OUR ACTUAL RESULTS
MAY DIFFER SIGNIFICANTLY FROM THE RESULTS PREDICTED IN OUR ANNUAL REPORT AND IN
FUTURE PUBLIC STATEMENTS. Factors that might cause such a difference include,
but are not limited to, the factors discussed below:

THE SUCCESS OF OUR DWDM INITIATIVE IS NOT GUARANTEED--IF THIS INITIATIVE IS
UNSUCCESSFUL, OUR OPERATING RESULTS MAY BE SEVERELY IMPAIRED.

    We plan to devote our research and development resources to the development
and marketing of new products and processes, including filters made of specially
treated glass which will be used as components in Dense Wavelength Division
Multiplexers (DWDMs). DWDMs are devices which, when inserted in fiber optic
cable lines, increase significantly the amount of data that such lines can
carry.

    While in recent quarters we have begun to market, produce and distribute
DWDM filters which meet certain of our customers' performance requirements, we
cannot guarantee that our DWDM initiative as a whole will be successful or that
we will succeed in developing and marketing DWDM filters or any other new
products. Also, certain domestic and foreign companies have begun marketing
products which employ technologies similar to our DWDM filter technology. We
cannot predict whether the DWDM filters which we have developed or will develop
in the future will be perceived in the marketplace as more cost-effective,
efficient or reliable than these competing products.

    Business prospects for the Company's DWDM filters remain uncertain largely
because of lack of visibility concerning future spending levels for
telecommunications equipment. The Company believes that downward trends in the
selling prices of DWDM filters may continue because of existing inventory
surpluses, increasing competitive pressure, and softening demand experienced by
telecommunications equipment providers.

    The long term success of the Company's DWDM filter products continues to
depend upon a number of factors, including the Company's timely completion of
ongoing product development efforts, continued ability to meet a set of rigorous
customer specifications, ability to control and reduce manufacturing costs to
generate acceptable profit margins, and success in reliably manufacturing such
products in sufficient quantities at acceptable yields to meet customer demand.

OUR QUARTERLY FINANCIAL RESULTS DEPEND ON A LARGE NUMBER OF FACTORS AND
THEREFORE MAY VARY QUARTER TO QUARTER--AS A RESULT, WE CANNOT PREDICT WITH A
HIGH DEGREE OF CERTAINTY OUR OPERATING RESULTS IN ANY PARTICULAR FISCAL QUARTER.

    Our quarterly operating results may vary significantly depending upon
factors such as:

          o    the timing of completion of significant orders

          o    the timing and amount of our research and development
               expenditures






          o    the costs of initial product production in connection with new
               products

          o    the timing of new product introductions -- both by us and by our
               competitors

          o    the timing and level of market acceptance of new products or
               enhanced versions of our existing products

          o    our ability to retain existing customers and customers' continued
               demand for our products and services

          o    our customers' inventory levels, and levels of demand for our
               customers' products and services

          o    competitive pricing pressures

We cannot be certain whether we will be able to grow or sustain revenues or
achieve or maintain profitability on a quarterly or annual basis or that levels
of revenue and/or profitability may not vary from one such period to another.

WE RELY ON A SMALL NUMBER OF CUSTOMERS AND CANNOT BE CERTAIN THEY WILL
CONSISTENTLY PURCHASE OUR PRODUCTS IN THE FUTURE.

    In the fiscal year ended June 30, 2001, our two largest customers
represented approximately 41% and 18%, respectively, of our total revenues. In
the fiscal year ended June 30, 2000, our two largest customers represented
approximately 46% and 11%, respectively, of our total revenues. In the fiscal
year ended June 30, 1999, our largest customer represented approximately 37% of
our total revenues. No other customer accounted for more than 10% of our
revenues during those periods.

    Our largest customer in recent years (representing 41% of 2001 revenues, 46%
of 2000 revenues and 37% of 1999 revenues) no longer places orders with us. We
attribute the loss of their business to the availability of lower cost
alternatives to our products.

    In the future, a small number of customers may continue to represent a
significant portion of our total revenues in any given period. We cannot be
certain that such customers will consistently purchase our products at any
particular rate over any subsequent period.

WE RELY HEAVILY UPON THE TALENTS OF OUR CHIEF EXECUTIVE OFFICER, THE LOSS OF
WHOM COULD SEVERELY DAMAGE OUR BUSINESS.

    Our performance depends to a large extent on a small number of key
scientific, technical, managerial, and marketing personnel. In particular, we
believe our success is highly dependent upon the services and reputation of our
Chief Executive Officer, Mr. Richard E. Forkey. Loss of Mr. Forkey's services
could severely damage our business.






WE MUST CONTINUE TO BE ABLE TO ATTRACT EMPLOYEES WITH THE SCIENTIFIC AND
TECHNICAL SKILLS THAT OUR BUSINESS REQUIRES--IF WE ARE UNABLE TO ATTRACT AND
RETAIN SUCH INDIVIDUALS, OUR BUSINESS COULD BE SEVERELY DAMAGED.

    Our ability to attract employees with a high degree of scientific and
technical talent is crucial to the success of our business. There is intense
competition for the services of such persons, and we cannot guarantee that we
will be able to attract and retain individuals possessing the necessary
qualifications.

WE HAVE A NUMBER OF LARGE, WELL-FINANCED COMPETITORS WHO HAVE RESEARCH AND
MARKETING CAPABILITIES THAT ARE SUPERIOR TO OURS.

    The industries in which we compete are highly competitive. Many of our
existing and potential competitors have greater financial resources and
manufacturing capabilities, more established and larger marketing and sales
organizations and larger technical staffs than we have. Other companies, some
with greater experience in the telecommunications, optics, semiconductor or
medical products industries, are seeking to produce products and services that
compete with our products and services.

WE ARE SUBJECT TO A HIGH DEGREE OF REGULATORY OVERSIGHT--WE CANNOT BE CERTAIN
THAT WE WILL CONTINUE TO RECEIVE THE NECESSARY REGULATORY APPROVALS.

    The FDA has allowed us to market the medical products we currently sell in
the United States. However, prior FDA approval may be required before we can
market additional medical products that we may develop in the future. We may
also seek to sell current or future medical products in a manner that requires
us to obtain FDA permission to market such products. We may also require the
regulatory approval or license of other federal, state or local agencies or
comparable agencies in other countries.

    We cannot be certain that we will continue to receive the FDA's permission
to market our current products or obtain the necessary regulatory permission,
approvals or licenses for the marketing of any of our future products. Also, we
cannot predict the impact on our business of FDA regulations or determinations
arising from future legislation or administrative action.

WE FACE RISKS INHERENT IN PRODUCT DEVELOPMENT AND PRODUCTION UNDER FIXED PRICE
CONTRACTS--WE CANNOT BE SURE THAT THESE CONTRACTS WILL BE PROFITABLE OVER TIME.

    A significant portion of our business has been devoted to research,
development and production under fixed price contracts. For our purposes, a
fixed price contract is any contract under which we will provide products or
services for a fixed price over an extended period of time (usually six months
or longer). In our 2001, 2000, and 1999 fiscal years, fixed price contracts
represented approximately 79%, 68% and 62%, respectively, of our total revenues.
We expect that revenues from fixed price contracts will continue to represent a
significant portion of our total revenues in future fiscal years.

    Because they involve performance over time, we cannot predict with certainty
the expenses involved in meeting our obligations under fixed price contracts.
Therefore, we can never be sure at the time we enter into any single fixed price
contract that such contract will be profitable for us. Cost overruns have
caused, and will likely continue to cause, individual fixed price contracts that
we enter into from time to time to be unprofitable.






THIRD PARTIES MAY INFRINGE ON OUR PATENTS--AS A RESULT, WE COULD INCUR
SIGNIFICANT EXPENSE IN PROTECTING OUR PATENTS OR NOT HAVE SUFFICIENT RESOURCES
TO PROTECT THEM.

    We hold a number of patents that are important to our business. Although we
are not currently aware of any past or present infringements of our patents, we
plan to protect these patents from infringement and obtain additional patents
whenever feasible. To this end, we have obtained confidentiality agreements from
our employees and consultants and others who have access to the design of our
products and other proprietary information. Protecting and obtaining patents,
however, is both time consuming and expensive. We therefore may not have the
resources necessary to assert all potential patent infringement claims or pursue
all patents that might be available to us.

THIRD PARTIES MAY CLAIM THAT WE HAVE INFRINGED ON THEIR PATENTS--AS A RESULT, WE
COULD BE PROHIBITED FROM USING ALL OR PART OF ANY TECHNOLOGY USED IN OUR
PRODUCTS.

    The technologies used or to be used in our advanced optical systems may
infringe upon patents or proprietary technology held or owned by other persons.
Should these persons claim a proprietary right to all or part of any technology
that we use in our products, such a claim, regardless of its merit, could
involve us in costly litigation. If successful, such a claim could also result
in us being unable to freely to use the technology that was the subject of the
claim, or sell products embodying such technology.

WE DEPEND ON THE AVAILABILITY OF CERTAIN KEY SUPPLIES AND SERVICES THAT ARE
AVAILABLE FROM ONLY A FEW SOURCES--IF WE EXPERIENCE DIFFICULTY WITH A SUPPLIER,
WE MAY HAVE DIFFICULTY FINDING ALTERNATIVE SOURCES OF SUPPLY.

    Certain key supplies used in our products, particularly precision grade
optical glass, are available from only a few sources, each of which is located
outside the United States. Also, outside vendors grind and polish certain of our
lenses and other optical components, such as prisms and windows. Based upon our
ordering experience to date, we believe the materials and services required for
the production of our products are currently available in sufficient quantities.
Our requirements are small relative to the total supply, and we are not
currently encountering problems with availability. However, this does not mean
that we will continue to have timely access to adequate supplies of essential
materials and services in the future or that supplies of these materials and
services will be available on satisfactory terms when the need arises. Our
business could be severely damaged if we become unable to procure essential
materials and services in adequate quantities and at acceptable prices.

    From time to time, certain of our products may be produced for us by
subcontractors, and our business is subject to the risk that these
subcontractors fail to make timely delivery. Our products and services are also
from time to time used as components of the products and services of other
manufacturers. We are therefore subject to the risk that manufacturers that
integrate our products or services into their own products or services are
unable to acquire essential supplies and services from third parties in a timely
fashion.

OUR CUSTOMERS MAY CLAIM THAT THE PRODUCTS WE SOLD THEM WERE DEFECTIVE--IF OUR
INSURANCE IS NOT SUFFICIENT TO COVER A CLAIM, WE WOULD BE LIABLE FOR THE EXCESS.

    Like any manufacturer, we are and always have been exposed to liability
claims resulting from the use of our products. We maintain product liability
insurance to cover us in the event of liability claims, and no such claims have
been asserted or threatened against us to date. However, we cannot be certain
that our insurance will be sufficient to cover all possible future product
liabilities.






WE WOULD BE LIABLE IF OUR BUSINESS OPERATIONS HARMED THE ENVIRONMENT--FAILURE TO
MAINTAIN COMPLIANCE WITH ENVIRONMENTAL LAWS COULD SEVERELY DAMAGE OUR BUSINESS.

    Our operations are subject to a variety of federal, state and local laws and
regulations relating to the protection of the environment. From time to time, we
use hazardous materials in our operations. Although we believe that we are in
compliance with all applicable environmental laws and regulations, our business
could be severely damaged by any failure to maintain such compliance.